Combined Astana city and Akmol village
|
Prevalence of HC among all
|
28.4%
|
24.0–32.7
|
118/416
|
44.1%
|
39.8–48.3
|
237/538
|
37.2%
|
34.1–40.3
|
355/954
|
Awareness among all cases of HC
|
47.5%
|
38.3–56.6
|
56/118
|
61.2%
|
54.9–67.4
|
145/237
|
56.6%
|
51.4–61.8
|
201/355
|
Treatment among all cases of HC
|
33.1%
|
24.4–41.7
|
39/118
|
44.3%
|
37.9–50.7
|
105/237
|
40.6%
|
35.4–45.7
|
144/355
|
Treatment among aware
|
67.9%
|
55.2–80.5
|
38/56
|
71.7%
|
64.3–79.1
|
104/145
|
70.7%
|
64.3–77.0
|
142/201
|
Control among all cases of HC
|
26.3%
|
18.2–34.3
|
31/118
|
21.9%
|
16.6–27.2
|
52/237
|
23.4%
|
19.0–27.8
|
83/355
|
Control among treated
|
79.5%
|
66.2–92.7
|
31/39
|
49.5%
|
39.8–59.2
|
52/105
|
57.6%
|
49.5–65.8
|
83/144
|
Astana city (urban, n = 480)
|
Prevalence of HC among all
|
38.2%
|
31.7–44.7
|
84/220
|
57.3%
|
51.3–63.4
|
149/260
|
48.5%
|
44.1–53.0
|
233/480
|
Awareness among all cases of HC
|
56.0%
|
45.1–66.8
|
47/84
|
72.5%
|
65.2–79.7
|
108/149
|
66.5%
|
60.4–72.6
|
155/233
|
Treatment among all cases of HC
|
36.9%
|
26.4–47.4
|
31/84
|
49.7%
|
41.5–57.8
|
74/149
|
45.1%
|
38.6–51.5
|
105/233
|
Treatment among aware
|
63.8%
|
49.6–78.1
|
30/47
|
68.5%
|
59.6–77.4
|
74/108
|
67.1%
|
59.6–74.6
|
104/155
|
Control among all cases of HC
|
29.8%
|
19.8–39.7
|
25/84
|
24.8%
|
17.8–31.9
|
37/149
|
26.6%
|
20.9–32.3
|
62/233
|
Control among treated
|
80.7%
|
65.9–95.4
|
25/31
|
50.0%
|
38.3–61.7
|
37/74
|
59.1%
|
49.5–68.6
|
62/105
|
Akmol village (rural, n = 474)
|
Prevalence of HC among all
|
17.4%
|
12.0–22.7
|
34/196
|
31.7%
|
26.2–37.2
|
88/278
|
25.7%
|
21.8–29.7
|
122/474
|
Awareness among all cases of HC
|
26.5%
|
10.8–42.1
|
9/34
|
42.1%
|
31.5–52.6
|
37/88
|
37.7%
|
29.0–46.4
|
46/122
|
Treatment among all cases of HC
|
23.5%
|
8.5–38.6
|
8/34
|
35.2%
|
25.0–45.4
|
31/88
|
32.0%
|
23.6–40.4
|
39/122
|
Treatment among aware
|
88.9%
|
63.3–114.5
|
8/9
|
81.1%
|
67.8–94.3
|
30/37
|
82.6%
|
71.2–94.0
|
38/46
|
Control among all cases of HC
|
17.7%
|
4.1–31.1
|
6/34
|
17.1%
|
9.0–25.1
|
15/88
|
17.2%
|
10.4–24.0
|
21/122
|
Control among treated
|
75.0%
|
36.3–113.7
|
6/8
|
48.4%
|
29.8–67.0
|
15/31
|
53.9%
|
37.5–70.2
|
21/39
|